CPTx
Cell & Gene Therapy · Health Care
Venture roundlatest round · Jan 2026 · 9 mo ago
2backers · Bayern Kapital, BlueYard Capital
$1Mgrants · 2 grants · CORDIS
2021founded
Overview
About Us We build the medicines we wish existed CPTx is a genetic medicines company redefining how we treat disease using immune-silent, redosable ssDNA as the foundation for safe, durable in vivo therapies.
Funding and backers
Latest round
Venture round
Jan 2026 · 9 mo ago
Grants
$1M
2 grants · CORDIS
Backers
2
Bayern Kapital, BlueYard Capital
The money's age
Fresh money
9 months since the last round · not hiring
Momentum
35/100
in the news, fresh money
Last sign of life
1 mo ago
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Sep 8
New executive CPTx appoints Matt Kane as Chief Financial Officer · cptx.bio
May 11
New executive CPTx appoints Edward Rebar as Chief Scientific Officer · The Manila Times
May 1
Won a grant $483k · CORDIS
Jan 19
Raised a round Venture round
Jan 1
Won a grant $525k · CORDIS
Nov 10, 2023
Raised a round Venture round
2021
Founded
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Grant | May 2026 | $483k | — | CORDIS |
| Venture round | Jan 2026 | — | — | handelsregister.de |
| Grant | Jan 2026 | $525k | — | CORDIS |
| Venture round | Nov 2023 | — | — | handelsregister.de |
Registers and programsofficial lists and records that name the company
| Legal entity | CPTx GmbH | its site |
| Registered | 7 Oct 2021 |
Backed byfrom the funds' portfolios and accelerator catalogs
Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
Metagenomi is an in vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for…
Vyriad engineers targeted virus platforms that bring durable in vivo gene therapies, genome editing, and oncolytic virotherapies to…
Ex-vivo gene therapy for phagocyte disorders. Somagenetix develops lentiviral HSC programs, starting with CGD—advancing safe, durable…
Developing scalable in-vivo genomic medicine for blood disorders.
Innorna is a clinical-stage biotechnology company engineering mRNA-based medicines to treat chronic diseases, power in vivo…
Carmine Therapeutics is pioneering a powerful new class of genetic medicines based on red blood cell extracellular vesicles (RBCEVs).
Connections
List
Graph
Found in company registers, site code, DNS and hiring. Each connection shows how sure we are and the evidence, with its source and date.
Shared investors
BlueYard CapitalVia a fund
Bayern KapitalVia a fund
Click a company to open it. Dashed lines are likely connections. The second step of the network is part of the Pro plan.
Owner
Same company
Same group
Likely
News
Symbol Lookup from Yahoo Finance
Search for ticker symbols for Stocks, Mutual Funds, ETFs, Indices and Futures on Yahoo! Finance.
Read more
Report
CPTx appoints Matt Kane as Chief Financial Officer
CPTx appoints Matt Kane as Chief Financial Officer
Read more
Report
CPTx appoints Matt Kane as Chief Financial Officer
Munich, Germany & San Francisco, California - September 8, 2026 - CPTx, a company developing next-generation non-viral in vivo CAR T therapies, today announced the appointment of Matt Kane as Chief Financial Officer (CFO). Matt Kane has led the developmen
Read more
Report
CPTx appoints Edward Rebar as Chief Scientific Officer
Munich, Germany & San Francisco, California - May 11, 2026 - CPTx, a company developing next-generation non-viral in vivo CAR T therapies, today announced the strengthening of its executive team with the appointment of Edward Rebar, PhD, as its Chief Scie
Read more
Report
CPTx appoints Edward Rebar as Chief Scientific Officer
CPTx appoints Edward Rebar as Chief Scientific Officer
Read more
Report
CPTx to present preclinical proof-of-principle of its DNA-based in vivo CAR T platform at ASGCT Annual Meeting
Oral presentation includes early readouts from preclinical testing of CAR-encoding episomal DNA delivered by targeted lipid nanoparticles CPTx will present two posters at ASGCT 2026 Munich, Germany - May 4, 2026 - CPTx, a company developing next-generatio
Read more
Report
CPTx to present preclinical proof-of-principle of its DNA-based in vivo CAR T platform at ASGCT Annual Meeting
Munich, Germany - May 4, 2026 - CPTx, a company developing next-generation non-viral in vivo CAR T therapies, today announced that it will deliver an oral presentation showing in vivo proof-of-principle of its immune-quiet, single-stranded DNA-based deliv
Read more
Report
Hendrik Dietz on "Making CAR T Truly Off the Shelf"
Our CEO, Hendrik Dietz aligned with the editorial team at The Medicine Maker to offer his view on "Making CAR T Truly Off the Shelf". He explores how a single infusion can transform a patient's own T cells into cancer-fighting machines using single-strand
Read more
Report
CPTx Unveils New Data at ESGCT Supporting ssDNA + LNP "Third Path" for In Vivo CAR-T
Munich, Germany - October 6, 2025 - CPTx today announced the presentation at the Annual Meeting of the European Society for Gene and Cell Therapy of new data supporting the company's differentiated "third path" approach to in vivo CAR T treatments for onc
Read more
Report
What role is precision medicine playing in transforming cancer treatment - and how are developers adapting?
Recently, our Commercial Operating Officer, Grant Boldt, PhD lent his thoughts to an industry article from Pharmaceutical Technology addressing the challenges posed by the limited bioavailability and stability in traditional drug development and delivery.
Read more
Report
Show more news